Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Tavelin, Björn
Alternative names
Publications (10 of 52) Show all publications
Kinhult, S., Tavelin, B., Löfgren, D., Rosenlund, L., Sandström, M., Strandeus, M. & Henriksson, R. (2023). Regional variation in usage of TTF (Optune) Regional variation i användningen av TTF vid glioblastombehandling: [Regional variation in usage of TTF (Optune)]. Läkartidningen, 120, Article ID 22158.
Open this publication in new window or tab >>Regional variation in usage of TTF (Optune) Regional variation i användningen av TTF vid glioblastombehandling: [Regional variation in usage of TTF (Optune)]
Show others...
2023 (English)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 120, article id 22158Article in journal (Refereed) Published
Abstract [en]

The standard treatment of glioblastoma, an aggressive brain tumour, includes radiotherapy combined with temozolomide. Based on a randomised trial, showing five months increased survival, TTF has been introduced in the management of patients with good performance status. Data from the Swedish national quality registry for CNS tumours have been analysed for TTF usage. The results demonstrate that 65 percent of the patients accepted treatment with TTF. More than half of the treated patients interrupted treatment due to low compliance or their own wish. Median treatment time was 164 days, with a range from 0 to 774 days. There was a large variation between different regions in how many patients were offered TTF treatment. A non-significant trend to better survival was seen for the group of TTF-treated patients compared to individually matched controls. In summary, TTF is a new treatment for glioblastoma, with potential to prolong survival also in real world patients. Today, the treatment is not offered equally to all patients, despite national guidelines.

Place, publisher, year, edition, pages
Sveriges läkarförbund, 2023
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-212051 (URN)2-s2.0-85164005813 (Scopus ID)
Note

Publicerad på Lakartidningen.se 2023-07-03

Available from: 2023-07-18 Created: 2023-07-18 Last updated: 2023-07-18Bibliographically approved
Egberg Thyme, K., Tavelin, B., Öster, I., Lindh, J. & Wiberg, B. (2022). Art therapy and self-image: A 5-year follow-up art therapy RCT study of women diagnosed with breast cancer. Palliative & Supportive Care, 20(4), 482-490
Open this publication in new window or tab >>Art therapy and self-image: A 5-year follow-up art therapy RCT study of women diagnosed with breast cancer
Show others...
2022 (Swedish)In: Palliative & Supportive Care, ISSN 1478-9515, E-ISSN 1478-9523, Vol. 20, no 4, p. 482-490Article in journal (Refereed) Published
Abstract [sv]

Mål: Denna uppföljningsstudie om upplevd självbild och psykofysisk nöd/psykiska symptom baserades på en ranomiserad kontrollerad studie av konstterapi på kvinnor med bröstcancer.

Metod: Syftet var att undersöka de långsiktiga effekterna av tidsbegränsad konstterapi med hjälp av instrumenten Strukturanalys av socialt beteende (SASB) och Symptom Check List-90 (SCL-90).

Resultat: Tre anslutningskluster i SASB visade signifikanta förändringar efter terapin: Autonomt jag (kluster 1), Accepterande själv (kluster 2) och Älskande själv (kluster 3). Klusterna 2 och 3 fortsatte att förändras till förmån för interventionsgruppen vid den 5-åriga uppföljningen. Det fanns inga signifikanta skillnader i SCL-90-resultaten mellan interventionsgruppen och kontrollgruppen i uppföljningsstudien.

Betydelse av resultat: Konstterapiinterventionen var både terapeutisk och psyko-pedagogisk. Slutsatsen av denna studie är att närmar sig känslor genom tidsbegränsad konstterapi verkar ha en långvarig effekt på det vidhäftande beteende som visas i SASB-modellen efter intervention, och denna effekt förblev 5 år senare.

Abstract [en]

Objective: This follow-up study on perceived self-image and psychophysical distress/psychic symptoms was based on a ranomized contolled study of art therapy on women with breast cancer.

Method: The aim was to examine the long-term effects of time-limited art therapy using the instruments of Structural Analysis of Social Behavior (SASB) and Symptom Check List-90 (SCL-90).

Results: Three attachment clusters of the SASB showed significant changes post therapy: Autonomous self (cluster 1), Accepting self (cluster 2), and Loving self (cluster 3). Clusters 2 and 3 continued to change in favor of the intervention group at the 5-year follow-up. There were no significant differences in the SCL-90 results between the intervention group and the control group in the follow-up study.

Significance of results: The art therapy intervention was both therapeutic and psycho-educative. The conclusion of this study is that approaching emotions through time-limited art therapy seems to have a long-lasting effect on the attachment behavioral system shown in the SASB model post intervention, and this effect remained 5 years later.

Place, publisher, year, edition, pages
Cambridges Institutes Press, 2022
Keywords
Art therapy, Breast cancer, Follow-up, SASB, SCL-90, Konstterapi, Bröstcancer, Uppföljning, SASA, SCL-90
National Category
Nursing
Identifiers
urn:nbn:se:umu:diva-187643 (URN)10.1017/S1478951521001437 (DOI)000779315900001 ()35876447 (PubMedID)2-s2.0-85117075785 (Scopus ID)
Note

Alternative title: "Konstterapi och självbild: En 5-årig uppföljning av konstterapi RCT-studie av kvinnor som diagnostiserats med bröstcancer"

Available from: 2021-09-16 Created: 2021-09-16 Last updated: 2023-03-24Bibliographically approved
Walladbegi, J., Henriksson, R., Tavelin, B., Svanberg, A., Larfors, G., Jädersten, M., . . . Jontell, M. (2022). Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial. Bone Marrow Transplantation, 57(2), 191-197
Open this publication in new window or tab >>Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial
Show others...
2022 (English)In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 57, no 2, p. 191-197Article in journal (Refereed) Published
Abstract [en]

Cryoprevention (CP) using ice (IC) is an effective strategy to prevent chemotherapy-induced oral mucositis (OM). However, the use of IC may cause adverse reactions and requires water of safe quality to minimize risk of serious infections. This randomized, blinded, parallel group, phase 3 trial was conducted in five Scandinavian centers. Eligible patients were diagnosed with multiple myeloma or lymphoma, scheduled to receive conditioning with high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation (ASCT). Patients were assigned to cooling with IC or a novel intraoral cooling device (ICD). The primary outcome was the highest OM score during the study period, expressed as peak value on the Oral Mucositis Assessment Scale (OMAS–total). When the entire study population (n = 172) was analyzed for peak OMAS–total, the two cooling methods were equally effective. However, when the lymphoma group was analyzed separately, the ICD significantly reduced the peak OMAS–total score to a greater extent compared to IC (x̄ ± SD; 1.77 ± 1.59 vs. 3.08 ± 1.50; p = 0.047). Combined with existing evidence, the results of the present trial confirm that CP is an effective method to prevent OM.

ClinicalTrials.gov. NCT03203733.

Place, publisher, year, edition, pages
Springer Nature, 2022
National Category
Hematology
Identifiers
urn:nbn:se:umu:diva-189557 (URN)10.1038/s41409-021-01512-6 (DOI)000713942300001 ()34728786 (PubMedID)2-s2.0-85118421846 (Scopus ID)
Funder
Vinnova, 2016-04171
Available from: 2021-11-16 Created: 2021-11-16 Last updated: 2022-07-12Bibliographically approved
Otten, J., Tavelin, B., Söderberg, S. & Rolandsson, O. (2022). Fasting C-peptide at type 2 diabetes diagnosis is an independent risk factor for total and cancer mortality. Diabetes/Metabolism Research Reviews, 38(3), Article ID e3512.
Open this publication in new window or tab >>Fasting C-peptide at type 2 diabetes diagnosis is an independent risk factor for total and cancer mortality
2022 (English)In: Diabetes/Metabolism Research Reviews, ISSN 1520-7552, E-ISSN 1520-7560, Vol. 38, no 3, article id e3512Article in journal (Refereed) Published
Abstract [en]

Aims: We assessed the association between insulin resistance and blood glucose concentrations at type 2 diabetes diagnosis and future development of diabetes-related complications and mortality.

Materials and Methods: This retrospective cohort study included 864 individuals with type 2 diabetes (median age 60 years) whose fasting C-peptide and HbA1c were measured at diabetes diagnosis. The median follow-up time until death or study end was 16.4 years (interquartile range 13.3−19.6). The association between C-peptide and mortality/complications was estimated by Cox regression adjusted for sex, age at diabetes diagnosis, smoking, hypertension, BMI, total cholesterol, and HbA1c. C-peptide and HbA1c were converted to Z scores before the Cox regression analysis.

Results: An increase by one standard deviation in fasting C-peptide at diabetes diagnosis was associated with all-cause (hazard ratio [HR] 1.33; 95% confidence intervals [CI] 1.12–1.58; p = 0.001) and cancer mortality (HR 1.51; 95% CI 1.13–2.01; p = 0.005) in the fully adjusted model. An increase by one standard deviation in HbA1c at diabetes diagnosis was associated with all-cause mortality (HR 1.24; 95% CI 1.07–1.44; p = 0.005), major cardiovascular events (HR 1.20; 95% CI 1.04–1.39; p = 0.015), stroke (HR 1.36; 95% CI 1.09–1.70; p = 0.006), and retinopathy (HR 1.54; 95% CI 1.34–1.76; p < 0.0001) in the fully adjusted model.

Conclusions: Fasting C-peptide at type 2 diabetes diagnosis is an independent risk factor for total and cancer-related mortality. Thus, treatment of type 2 diabetes should focus not only on normalising blood glucose levels but also on mitigating insulin resistance.

Place, publisher, year, edition, pages
John Wiley & Sons, 2022
Keywords
cancer mortality, diabetes mellitus type 2, insulin resistance, mortality
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:umu:diva-190001 (URN)10.1002/dmrr.3512 (DOI)000720975500001 ()34780669 (PubMedID)2-s2.0-85119586636 (Scopus ID)
Funder
Norrbotten County CouncilRegion Västerbotten
Available from: 2021-12-07 Created: 2021-12-07 Last updated: 2022-07-12Bibliographically approved
Tavelin, B. & Malmström, A. (2022). Sex Differences in Glioblastoma - Findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999–2018. Journal of Clinical Medicine, 11(3), Article ID 486.
Open this publication in new window or tab >>Sex Differences in Glioblastoma - Findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999–2018
2022 (English)In: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 11, no 3, article id 486Article in journal (Refereed) Published
Abstract [en]

Sex disparities in glioblastoma (GBM) have received increasing attention. Sex‐related differences for several molecular markers have been reported, which could impact on clinical factors and outcomes. We therefore analyzed data on all patients with GBM reported to the Swedish National Quality Registry for Primary Brain Tumors, according to sex, with a focus on prognostic factors and survival. All glioma patients registered during 20 years, from 1 January 1999 until 31 December 2018, with SNOMED codes 94403, 94413, and 94423, were analyzed. Chi2‐test, log‐rank test, and Kaplan–Meier analyses were performed. We identified 5243 patients, of which 2083 were females and 3160 males, resulting in a ratio of 1:1.5. We found sex related differences, with women having diagnostic surgery at a significantly higher age (p = 0.001). Women were also reported to have a worse preoperative performance status (PPS) (<0.001). There was no gender difference for the type of surgery performed. For women with radical surgery, overall survival was slightly better than for men (p = 0.045). The time period did not influence survival, neither for 1999–2005 nor 2006– 2018, after temozolomide treatment was introduced (p = 0.35 and 0.10, respectively). In the multivariate analysis including sex, age, surgery, and PPS, a survival advantage was noted for women, but this was not clinically relevant (HR = 0.92, p = 0.006). For patients with GBM; sex‐related differences in clinical factors could be identified in a population‐based cohort. In this dataset, for survival, the only advantage noted was for women who had undergone radical surgery, although this was clinically almost negligible.

Place, publisher, year, edition, pages
MDPI, 2022
Keywords
Clinical factors, Glioblastoma, Population‐based cohort, Sex differences, Survival
National Category
Surgery Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-191733 (URN)10.3390/jcm11030486 (DOI)000755279600001 ()2-s2.0-85122899798 (Scopus ID)
Funder
Swedish Cancer SocietyCancerforskningsfonden i Norrland
Available from: 2022-01-24 Created: 2022-01-24 Last updated: 2023-09-05Bibliographically approved
Patthey, A., Boman, K., Tavelin, B., Lindquist, D., Lundin, E. & Hultdin, M. (2021). Combination of aneuploidy and high S-phase fraction indicates increased risk of relapse in stage I endometrioid endometrial carcinoma. Acta Oncologica, 60(9), 1218-1224
Open this publication in new window or tab >>Combination of aneuploidy and high S-phase fraction indicates increased risk of relapse in stage I endometrioid endometrial carcinoma
Show others...
2021 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 60, no 9, p. 1218-1224Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION: Endometrioid endometrial carcinoma is a cancer type with generally excellent prognosis when diagnosed at an early stage, but there is a subset of patients with relapsing disease in spite of early diagnosis and surgical treatment. There is a need to find prognostic markers to identify these patients with increased risk of relapse. Depth of myometrial invasion, histological grade, and presence of lymphovascular invasion are known risk factors. DNA content (ploidy) and proliferation measured as S-phase fraction (SPF) have been discussed as prognostic markers but need additional evaluation.

MATERIAL AND METHODS: We evaluated relapse-free survival (RFS) with respect to ploidy and SPF, which was analyzed by flow cytometry on fresh tumor tissue, in a cohort of 1001 women treated for stage I endometrioid endometrial carcinoma in northern Sweden during the period of 1993-2010, with a median follow up time of 12.0 years. Data were obtained from historical records.

RESULTS: In simple analysis, both aneuploidy and high SPF were associated to increased risk of relapse with hazard ratios (HR) 2.37 (95% CI 1.52-3.70) and 1.94 (95% CI 1.24-3.02), respectively. Our data also confirmed stage, tumor grade, and ploidy as independent prognostic markers in an age adjusted cox regression multivariable analysis but we did not find SPF to contribute to prognosis. However, the combination of aneuploidy and high SPF identified a group of patients with increased risk of relapse, HR 2.02 (95% CI 1.19-3.44).

CONCLUSION: In this study, which is the largest study of ploidy and SPF in stage I endometrioid endometrial carcinoma using fresh frozen tissue, aneuploidy was shown to be an independent prognostic marker. Furthermore, the combination of aneuploidy and high SPF could be used to identify patients with increased risk of relapse.

Place, publisher, year, edition, pages
Taylor & Francis Group, 2021
Keywords
Endometrioid Endometrial Carcinoma, Ploidy, Prognosis, S-phase fraction
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-185073 (URN)10.1080/0284186X.2021.1939146 (DOI)000665673800001 ()34156893 (PubMedID)2-s2.0-85108629114 (Scopus ID)
Funder
Region Västerbotten
Available from: 2021-06-23 Created: 2021-06-23 Last updated: 2023-03-24Bibliographically approved
Andersson, A., Enblad, G., Erlanson, M., Johansson, A. S., Molin, D., Tavelin, B., . . . Melin, B. S. (2021). High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma: is there a need for intervention in long-term survivors?. Upsala Journal of Medical Sciences, 126, Article ID e6117.
Open this publication in new window or tab >>High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma: is there a need for intervention in long-term survivors?
Show others...
2021 (English)In: Upsala Journal of Medical Sciences, ISSN 0300-9734, E-ISSN 2000-1967, Vol. 126, article id e6117Article in journal (Refereed) Published
Abstract [en]

Background: Hodgkin lymphoma (HL) patients have a good prognosis after adequate treatment. Previous treatment with mantle field irradiation has been accompanied by an increased long-term risk of cardiovascular disease (CVD). This study identified co-morbidity factors for the development of cardiovascular side effects and initiated an intervention study aimed to decrease morbidity and mortality of CVD in HL survivors.

Design: Hodgkin lymphoma patients aged ≤45 years diagnosed between 1965 and 1995 were invited to participate. In total, 453 patients completed a questionnaire that addressed co-morbidity factors and clinical symptoms. Of these, 319 accepted to participate in a structured clinical visit. The statistical analyses compared individuals with CVD with those with no CVD.

Results: Cardiovascular disease was reported by 27.9%. Radiotherapy (odds ratio [OR]: 3.27), hypertension and hypercholesterolemia were shown to be independent risk factors for the development of CVD. The OR for CVD and valve disease in patients who received radiotherapy towards mediastinum was 4.48 and 6.07, respectively. At clinical visits, 42% of the patients were referred for further investigation and 24% of these had a cardiac ultrasound performed due to previously unknown heart murmurs.

Conclusion: Radiotherapy towards mediastinum was an independent risk factor for CVD as well as hypercholesterolemia and hypertension. A reasonable approach as intervention for this cohort of patients is regular monitoring of hypertension and hypercholesterolemia and referral to adequate investigation when cardiac symptoms appear. Broad knowledge about the side effects from radiotherapy in the medical community and well-structured information regarding late side effects to the patients are all reasonable approaches as late effects can occur even 40 years after cancer treatment.

Place, publisher, year, edition, pages
Upsala Medical Society, 2021
Keywords
cardiovascular side effects, Hodgkin lymphoma, intervention, survivorship
National Category
Cardiac and Cardiovascular Systems Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-184454 (URN)10.48101/ujms.v126.6117 (DOI)000683141500001 ()33889307 (PubMedID)2-s2.0-85107246635 (Scopus ID)
Available from: 2021-06-15 Created: 2021-06-15 Last updated: 2023-09-05Bibliographically approved
Lindgren, M., Jansson, M., Tavelin, B., Dirix, L., Vermeulen, P. & Nyström, H. (2021). Type IV collagen as a potential biomarker of metastatic breast cancer. Clinical and Experimental Metastasis, 38(2), 175-185
Open this publication in new window or tab >>Type IV collagen as a potential biomarker of metastatic breast cancer
Show others...
2021 (English)In: Clinical and Experimental Metastasis, ISSN 0262-0898, E-ISSN 1573-7276, Vol. 38, no 2, p. 175-185Article in journal (Refereed) Published
Abstract [en]

No reliable, non-invasive biomarker of metastatic breast cancer (mBC) exists: circulating CA15-3 (cCA15-3) is the marker mostly used to monitor mBC. Circulating collagen IV (cCOLIV) has been evaluated in other metastatic cancers and has been found to be a promising biomarker. The overarching aim of this study was to evaluate cCOLIV as a potential biomarker in patients with mBC. The first aim was to determine the levels of cCOL IV and cCA15-3 in patients with healthy controls, primary breast cancer (pBC) and mBC. The second aim was to compare levels of cCOLIV and cCA15-3 in patients with different metastatic sites of BC. The third aim was to investigate the prognostic value of cCOLIV and cCA15-3 for mBC patients. The fourth aim was to analyse whether a combination of the two biomarkers was more accurate in detecting mBC than a single marker. Lastly, we investigated the tissue expression levels of COLIV in BC bone metastases (BM) and liver metastases (LM). Plasma levels of cCOLIV and cCA15-3 from healthy controls and patients with pBC and mBC were measured. COLIV expression in tissue from patients with LM and BM was analysed using immunohistochemistry. Clinical and survival data were collected from medical charts. The levels of cCOLIV and cCA15-3 were significantly elevated in mBC patients compared with healthy controls and pBC patients. No differences in cCOLIV and cCA15-3 levels were found based on the metastatic site. High levels of cCOLIV, but not cCA15-3, correlated with poorer survival. cCOLIV alone and the combination of cCA15-3 and cCOLIV were superior to cCA15-3 at detecting mBC. COL IV was highly expressed in the tissue of LM and BM. Our study suggests that cCOLIV is a potential marker to monitor patients with BC.

Place, publisher, year, edition, pages
Springer, 2021
Keywords
Biomarkers, Breast cancer, CA 15-3, Collagen IV, Metastases
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-181664 (URN)10.1007/s10585-021-10082-2 (DOI)000624362300001 ()33655422 (PubMedID)2-s2.0-85102057579 (Scopus ID)
Funder
Swedish Research CouncilWallenberg FoundationsKnut and Alice Wallenberg FoundationVästerbotten County CouncilSwedish Cancer SocietyCancerforskningsfonden i NorrlandThe Kempe Foundations
Available from: 2021-03-29 Created: 2021-03-29 Last updated: 2022-10-31Bibliographically approved
Fransson, P., Nilsson, P., Gunnlaugsson, A., Beckman, L., Tavelin, B., Norman, D., . . . Widmark, A. (2021). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. The Lancet Oncology, 22(2), 235-245
Open this publication in new window or tab >>Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Show others...
2021 (English)In: The Lancet Oncology, ISSN 1470-2045, E-ISSN 1474-5488, Vol. 22, no 2, p. 235-245Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: The HYPO-RT-PC trial compared conventionally fractionated radiotherapy with ultra-hypofractionated radiotherapy in patients with localised prostate cancer. Ultra-hypofractionation was non-inferior to conventional fractionation regarding 5-year failure-free survival and toxicity. We aimed to assess whether patient-reported quality of life (QOL) differs between conventional fractionation and ultra-hypofractionation up to 6 years after treatment in the HYPO-RT-PC trial.

METHODS: HYPO-RT-PC is a multicentre, open-label, randomised, controlled, non-inferiority, phase 3 trial done in 12 centres (seven university hospitals and five county hospitals) in Sweden and Denmark. Inclusion criteria were histologically verified intermediate-to-high-risk prostate cancer (defined as T1c-T3a with one or two of the following risk factors: stage T3a; Gleason score ≥7; and prostate-specific antigen 10-20 ng/mL with no evidence of lymph node involvement or distant metastases), age up to 75 years, and WHO performance status 0-2. Participants were randomly assigned (1:1) to conventional fractionation (78·0 Gy in 39 fractions, 5 days per week for 8 weeks) or ultra-hypofractionation (42·7 Gy in seven fractions, 3 days per week for 2·5 weeks) via a minimisation algorithm with stratification by trial centre, T-stage, Gleason score, and prostate-specific antigen. QOL was measured using the validated Prostate Cancer Symptom Scale (PCSS) and European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) at baseline, the end of radiotherapy, months 3, 6, 12, and 24 after radiotherapy, every other year thereafter up to 10 years, and at 15 years. The primary endpoint (failure-free survival) has been reported elsewhere. Here we report QOL, a secondary endpoint analysed in the per-protocol population, up to 6 years after radiotherapy. The HYPO-RT-PC trial is registered with the ISRCTN registry, ISRCTN45905321.

FINDINGS: Between July 1, 2005, and Nov 4, 2015, 1200 patients were enrolled and 1180 were randomly assigned (conventional fractionation n=591, ultra-hypofractionation n=589); 1165 patients (conventional fractionation n=582, ultra-hypofractionation n=583) were included in this QOL analysis. 158 (71%) of 223 patients in the conventional fractionation group and 146 (66%) of 220 in the ultra-hypofractionation group completed questionnaires at 6 years. The median follow-up was 48 months (IQR 25-72). In seven of ten bowel symptoms or problems the proportion of patients with clinically relevant deteriorations at the end of radiotherapy was significantly higher in the ultra-hypofractionation group than in the conventional fractionation group (stool frequency [p<0·0001], rush to toilet [p=0·0013], flatulence [p=0·0013], bowel cramp [p<0·0001], mucus [p=0·0014], blood in stool [p<0·0001], and limitation in daily activity [p=0·0014]). There were no statistically significant differences in the proportions of patients with clinically relevant acute urinary symptoms or problems (total 14 items) and sexual functioning between the two treatment groups at end of radiotherapy. Thereafter, there were no clinically relevant differences in urinary, bowel, or sexual functioning between the groups. At the 6-year follow-up there was no difference in the incidence of clinically relevant deterioration between the groups for overall urinary bother (43 [33%] of 132 for conventional fractionation vs 33 [28%] of 120 for ultra-hypofractionation; mean difference 5·1% [95% CI -4·4 to 14·6]; p=0·38), overall bowel bother (43 [33%] of 129 vs 34 [28%] of 123; 5·7% [-3·8 to 15·2]; p=0·33), overall sexual bother (75 [60%] of 126 vs 59 [50%] of 117; 9·1% [-1·4 to 19·6]; p=0·15), or global health/QOL (56 [42%] of 134 vs 46 [37%] of 125; 5·0% [-5·0 to 15·0]; p=0·41).

INTERPRETATION: Although acute toxicity was higher for ultra-hypofractionation than conventional fractionation, this long-term patient-reported QOL analysis shows that ultra-hypofractionation was as well tolerated as conventional fractionation up to 6 years after completion of treatment. These findings support the use of ultra-hypofractionation radiotherapy for intermediate-to-high-risk prostate cancer.

FUNDING: The Nordic Cancer Union, the Swedish Cancer Society, and the Swedish Research Council.

Place, publisher, year, edition, pages
Elsevier, 2021
National Category
Nursing Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-179385 (URN)10.1016/S1470-2045(20)30581-7 (DOI)000615917800030 ()33444529 (PubMedID)2-s2.0-85100046913 (Scopus ID)
Funder
Swedish Research CouncilSwedish Cancer Society
Available from: 2021-02-01 Created: 2021-02-01 Last updated: 2023-09-05Bibliographically approved
Walladbegi, J., Svanberg, A., Jontell, M., Henriksson, R., Schjesvold, F., Larfors, G., . . . Jadersten, M. (2020). A blinded, randomized, parallel group, comparative investigation of a novel device (Cooral) for cryoprevention of oral mucositis. Paper presented at ESMO Virtual Congress, SEP 19-OCT 18, 2020, ELECTR NETWORK. Annals of Oncology, 31, S1167-S1167
Open this publication in new window or tab >>A blinded, randomized, parallel group, comparative investigation of a novel device (Cooral) for cryoprevention of oral mucositis
Show others...
2020 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 31, p. S1167-S1167Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Elsevier, 2020
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-176544 (URN)10.1016/j.annonc.2020.08.2267 (DOI)000573469102665 ()
Conference
ESMO Virtual Congress, SEP 19-OCT 18, 2020, ELECTR NETWORK
Note

Supplement: 4

Meeting Abstract: LBA37

Available from: 2020-11-11 Created: 2020-11-11 Last updated: 2020-11-11Bibliographically approved
Organisations

Search in DiVA

Show all publications